Unicycive Therapeutics UNCY 深 滬
等待開盤 08-30 09:30:00 美东时间
4.10
-0.100
-2.38%
華盛通- 最 高4.2591
- 今 開4.17
- 成交量 32.35万股
- 最 低 4.095
- 昨 收 4.20
- 總市值 5182.77万
- 52周最高 11.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.40
- 委 比 -89.63%
- 總股本 1264.09万
- 歷史最高 87.30
- 量 比 1.07
- 振 幅 3.91%
- 歷史最低 2.02
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Unicycive Therapeutics to Participate in Upcoming Investor Events in September
Unicycive Therapeutics Inc. announced that CEO Shalabh Gupta, M.D., will participate in two investor events in September. The first is a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, and the second is a virtual fireside chat with Truist Securities on September 17, 2025. The company is developing therapies for kidney diseases, including oxylanthanum carbonate for hyperphosphatemia in chronic k...
08-26 11:00
Unicycive Faces Securities Lawsuit Over Drug Claims
Unicycive Therapeutics ( ($UNCY) ) has provided an update. On August 15, 2025, ...
08-19 04:53
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease
Unicycive Therapeutics announced the issuance of U.S. Patent 12,377,082 for UNI-494 to treat Chronic Kidney Disease (CKD), supporting intellectual property protection until 2040. UNI-494 is a novel nicotinamide ester derivative targeting mitochondrial dysfunction in kidney diseases. The company has completed a Phase I clinical study and received Orphan Drug Designation for preventing Delayed Graft Function (DGF) in kidney transplant patients. UNI...
08-18 11:05
Unicycive Therapeutics Q2 EPS $(0.52) Beats $(0.78) Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.78) by 32.9 percent. This is a 65.33 percent increase over losses of $(1.50) per share
08-14 19:16
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology
A Phase 2 clinical trial of Oxylanthanum Carbonate (OLC) showed that the investigational phosphate binder effectively controlled serum phosphate levels in over 90% of chronic kidney disease (CKD) patients on dialysis with hyperphosphatemia. OLC was well-tolerated, with only 4% of patients discontinuing due to adverse events, and required a low pill burden (three or fewer tablets/day for two-thirds of patients). The trial results support OLC's pot...
07-24 12:00
Unicycive Regains Nasdaq Compliance After Stock Split
Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. On July 8, 2025,...
07-08 21:28
Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Unicycive Therapeutics reache Neuer Marktanhängigkeit an der NASDAQ nach erfolgreicher Umsetzung eines 1:10-rückwärtigen Aktiensplits.
07-08 12:30
Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Unicycive Therapeutics首席执行官Shalabh Gupta博士将于7月14日美国东部时间上午11点，在H.C. Wainwright 4th Annual Kidney Virtual Conference上参与炉边谈话。会议链接可在公司网站投资者部分访问。Unicycive致力于开发肾脏疾病治疗药物，重点为oxylanthanum carbonate（治疗慢性肾病患者高磷血症）和UNI-494（针对急性肾损伤，已获FDA孤儿药指定用于预防肾移植患者的延迟移植物功能）。
07-07 11:00
Unicycive drops 25% following Complete Response Letter
Unicycive Therapeutics (NASDAQ:UNCY) is down ~25% after disclosing it has received a Complete Response Letter from the U.S. FDA for its application for oxylanthanum carbonate. The candidate aims to tr...
06-30 23:04
